Company Encyclopedia
View More
name
Biofrontera
BFRI.US
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo.
4.338 T
BFRI.USMarket value -Rank by Market Cap -/-

Financial Score

16/11/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking102/180
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-1191.73%E
    • Profit Margin-47.28%E
    • Gross Margin70.74%A
  • Growth ScoreD
    • Revenue YoY5.11%C
    • Net Profit YoY-36.89%D
    • Total Assets YoY-16.75%E
    • Net Assets YoY-146.67%E
  • Cash ScoreC
    • Cash Flow Margin-211.50%D
    • OCF YoY5.11%C
  • Operating ScoreA
    • Turnover2.19A
  • Debt ScoreE
    • Gearing Ratio116.74%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Roth MKM Reaffirms Their Buy Rating on Biofrontera (BFRI)

    Roth MKM's Jonathan Aschoff reaffirmed a Buy rating on Biofrontera (BFRI) with a $9.00 price target. Aschoff, who covers the Healthcare sector, has an average return of -18.3% and a 30.59% success rate. Benchmark Co.'s Bruce Jackson also issued a Buy rating, while TR reiterated a Hold rating on Biofrontera.

    Tip Ranks·
    US
    BFRI
    -8.13%
    Tip Ranks·
    US
    BFRI
    -8.13%

    Biofrontera Inc. Reports Q3 2025 Results and Strategic Moves

    Biofrontera Inc. reported Q3 2025 results with revenues declining to $7.0 million from $9.0 million in Q3 2024 due to prior advanced purchases. Operating expenses decreased by 5%, and a net loss of $6.6 million was recorded. Strategic moves include acquiring U.S. assets from Biofrontera AG and divesting Xepi cream. The acquisition of Ameluz and RhodoLED assets is expected to boost margins and profitability. The company anticipates substantial revenue growth in Q4 and remains focused on expanding Ameluz's use and improving financial leverage through strategic acquisitions and partnerships.

    Tip Ranks·
    US
    BFRI
    -8.13%
    Tip Ranks·
    US
    BFRI
    -8.13%

    Biofrontera, Inc. Navigates Mixed Earnings Call

    Biofrontera, Inc.'s Q3 earnings call revealed mixed financial results. Positive aspects included stable year-to-date revenues, strategic expansions, patent approval, and financial agreements. However, challenges such as a 22% decline in Q3 revenues, increased legal costs, and a higher net loss were noted. The company anticipates strong revenue growth in Q4 2025, driven by strategic agreements and investments, aiming for cash flow breakeven by fiscal year 2026.

    Tip Ranks·
    US
    BFRI
    -8.13%
    Tip Ranks·
    US
    BFRI
    -8.13%

    Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

    Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint ...

    GlobeNewswire·
    US
    AURA
    0.00%
    GlobeNewswire·
    US
    AURA
    0.00%

    Biofrontera | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 6.988 M

    LB filings·
    US
    BFRI
    -8.13%
    LB filings·
    US
    BFRI
    -8.13%